Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Megan E V Caram"'
Autor:
Megan E. V. Caram, Kyle Kumbier, Phoebe A. Tsao, Jennifer Burns, Jordan B. Sparks, Kristian D. Stensland, Zachery R. Reichert, Joshi J. Alumkal, Brent K. Hollenbeck, Vahakn Shahinian, Alexander Tsodikov, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Metastatic castration‐resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration‐resistant diagnosis. Optimal first‐line therapy for those with different
Externí odkaz:
https://doaj.org/article/e87d252553e64f07b78df5cbebfcca3e
Autor:
Kassem S. Faraj, Samuel R. Kaufman, Lindsey A. Herrel, Avinash Maganty, Mary Oerline, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22325-22332 (2023)
Abstract Introduction Some worry that physician practices acquired by private equity may increase the use of services to maximize revenue. We assessed the effects of private equity acquisition on spending, use of treatment, and diagnostic testing in
Externí odkaz:
https://doaj.org/article/63873959c5394b72920fa809b8c1255b
Autor:
Noah Krampe, Samuel R. Kaufman, Mary K. Oerline, Dawson Hill, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck, Avinash Maganty
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17346-17355 (2023)
Abstract Background Despite clinical guidelines advocating for use of conservative management in specific clinical scenarios for men with prostate cancer, there continues to be tremendous variation in its uptake. This variation may be amplified among
Externí odkaz:
https://doaj.org/article/68511507ff54470788d267bd51b9187a
Autor:
Phoebe A. Tsao, Jennifer Burns, Kyle Kumbier, Jordan B. Sparks, Shami Entenman, Lindsey E. Bloor, Amy S. B. Bohnert, Ted A. Skolarus, Megan E. V. Caram
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16490-16501 (2023)
Abstract Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. Methods We used national Veter
Externí odkaz:
https://doaj.org/article/d95095a5a3ee48ecb1498054bf1924b9
Autor:
Avinash Maganty, Samuel R. Kaufman, Mary K. Oerline, Kassem S. Faraj, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Objective To examine the effect of urologist participation in value‐based payment models on the initial management of men with newly diagnosed prostate cancer. Methods Medicare beneficiaries with prostate cancer diagnosed between 2017 and
Externí odkaz:
https://doaj.org/article/fd854d2fc477459791dcc0a0ee327001
Autor:
Megan E. V. Caram, Kyle Kumbier, Jennifer Burns, Jordan B. Sparks, Phoebe A. Tsao, Kristian D. Stensland, Samuel L. Washington III, Brent K. Hollenbeck, Vahakn Shahinian, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6945-6955 (2023)
Abstract Background Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide
Externí odkaz:
https://doaj.org/article/8e7c0dabb2ab4edb91d46c692eb5454b
Autor:
Christina Hunter Chapman, Megan E. V. Caram, Archana Radhakrishnan, Alexander Tsodikov, Curtiland Deville, Jennifer Burns, Alexander Zaslavsky, Michael Chang, John T. Leppert, Timothy Hofer, Anne E. Sales, Sarah T. Hawley, Brent K. Hollenbeck, Ted A. Skolarus
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7903-7912 (2019)
Abstract Background Although prostate‐specific antigen (PSA) testing is used for prostate cancer detection and posttreatment surveillance, thresholds in these settings differ. The screening cutoff of 4.0 ng/mL may be inappropriately used during pos
Externí odkaz:
https://doaj.org/article/9969c262f1ef4d6a8305c4bc204e4b20
Autor:
Lillian Y. Lai, Samuel R. Kaufman, Mary Oerline, Megan E. V. Caram, Avinash Maganty, Vahakn B. Shahinian, Brent K. Hollenbeck
Publikováno v:
Urology Practice. 10:230-235
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1d661c04e9f1b159b4f6c628e94c93e
https://doi.org/10.1097/upj.0000000000000390
https://doi.org/10.1097/upj.0000000000000390
Autor:
Ted A. Skolarus, Sarah T. Hawley, Daniela A. Wittmann, Jane Forman, Tabitha Metreger, Jordan B. Sparks, Kevin Zhu, Megan E. V. Caram, Brent K. Hollenbeck, Danil V. Makarov, John T. Leppert, Jeremy B. Shelton, Vahakn Shahinian, Sriram Srinivasaraghavan, Anne E. Sales
Publikováno v:
Implementation Science, Vol 13, Iss 1, Pp 1-11 (2018)
Abstract Background Men with prostate cancer are often castrated with long-acting injectable drugs termed androgen deprivation therapy (ADT). Although many benefit, ADT is also used in patients with little or nothing to gain. The best ways to stop th
Externí odkaz:
https://doaj.org/article/8b77ab2a8ebe4a8596b7eb61947aa8c1
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (docetaxel, abirat
Externí odkaz:
https://doaj.org/article/03ffa4bc292a4f0a94277c0e102816e8